TG Therapeutics Announces Data Presentations Schedule
TG Therapeutics, Inc. has recently shared an exciting update regarding the scheduling of presentations that will showcase data related to BRIUMVI (ublituximab) at the American Academy of Neurology (AAN) annual meeting in 2025. The meeting is set to take place from April 5 to April 9, drawing attention from neurologists and experts in multiple sclerosis (MS) treatment.
Details of the BRIUMVI Presentations
At the upcoming AAN meeting, TG Therapeutics will highlight findings from their clinical trials that emphasize the efficacy of BRIUMVI in treating relapsing forms of multiple sclerosis. Abstracts detailing these findings are now accessible online for those interested.
Poster Presentation Overview
Among the key presentations, the following posters are noteworthy:
- Title: No Association Between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-term Ublituximab Treatment
- Date/Time: Monday, April 7, from 5:00 PM–6:00 PM PT
- Session: P7: Multiple Sclerosis: Disease-modifying Therapies
- Abstract Number: 4695
- Lead Author: Dr. Bruce Cree
- Title: Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-World Observational Survey (ENAMOR)
- Date/Time: Monday, April 7, from 5:00 PM–6:00 PM PT
- Session: P7: Multiple Sclerosis: Disease-modifying Therapies
- Abstract Number: 5121
- Lead Author: Dr. Ed Fox
- Title: ENABLE: The First Phase 4 Observational Study for Patients with Relapsing MS Treated with Ublituximab
- Date/Time: Monday, April 7, from 5:00 PM–6:00 PM PT
- Session: P7: Multiple Sclerosis: Disease-modifying Therapies
- Abstract Number: 4773
- Lead Author: Dr. Ed Fox
- Title: Five years of Ublituximab in Relapsing Multiple Sclerosis: Additional Results from the Open-label Extension of ULTIMATE I and II Studies
- Date/Time: Wednesday, April 9, from 8:00 AM–9:00 AM PT
- Session: P11: Clinical and Translational Research in MS
- Abstract Number: 2928
- Lead Author: Dr. Bruce Cree
- Title: Efficacy and Safety of a Modified Ublituximab Regimen (ENHANCE)
- Date/Time: Wednesday, April 9, from 8:00 AM–9:00 AM PT
- Session: P11: Clinical and Translational Research in MS
- Abstract Number: 4799
- Lead Author: Dr. John Foley
What is BRIUMVI?
BRIUMVI (ublituximab) is an innovative monoclonal antibody that engages uniquely with CD20-expressing B-cells. Utilizing a process called glycoengineering, BRIUMVI is formulated to promote effective B-cell depletion while minimizing necessary dosage. This medication is specifically designed for adults suffering from relapsing forms of MS and is recognized for addressing challenges associated with conventional treatments.
The Importance of Clinical Trials
Clinical trials played a crucial role in the development and approval of BRIUMVI. The ULTIMATE I and II trials, for instance, evaluated the safety and efficacy of this treatment over an extensive period of 96 weeks among diverse patient groups. This thorough investigation gathered valuable insights that are instrumental in guiding treatment protocols and patient care strategies.
Patient Outcomes and Real-World Application
Data derived from real-world observational studies, like the ENAMOR survey, help present a broader understanding of patient experiences with BRIUMVI. Such studies illustrate how well patients tolerate infusion protocols in typical medical settings, thus helping healthcare providers make informed decisions regarding treatment plans.
Looking to the Future
As TG Therapeutics continues to advance its research, it remains committed to providing innovative solutions addressing the insidious challenges of MS. The forthcoming AAN presentations are anticipated to invigorate discussions on the experiences of patients treated with BRIUMVI and the ongoing commitment to improving their quality of life.
Frequently Asked Questions
What is BRIUMVI?
BRIUMVI is a monoclonal antibody treatment designed for adults with relapsing forms of multiple sclerosis, focusing on efficient B-cell depletion.
When will the presentations take place?
The BRIUMVI presentations will be held at the AAN annual meeting from April 5 to April 9 in 2025.
Who are some of the key authors presenting data?
Dr. Bruce Cree and Dr. Ed Fox are among the lead authors presenting at the conference.
How long has BRIUMVI been studied?
BRIUMVI has undergone several extensive clinical trials, including the ULTIMATE I and II trials over 96 weeks.
What impact do real-world studies have on treatment?
Real-world studies provide valuable insights into patient experiences with BRIUMVI, enhancing the understanding of its efficacy and tolerability in everyday healthcare settings.
